Retrospective study of effect of 75 mg once a day starting immediately before and continuing for 1 month post-transplant for prophylaxis against renal vein thrombosis.
Out of 480 patients, post biopsy bleeding was present in 8 (1.6%), early post- transplant bleeding in 3 (1%) and re-exploration for bleeding in 3 (1%).
A consecutive series of 105 cadaveric renal transplants treated with aspirin 150 mg daily for the first 3 months after transplantation was compared with an untreated historical control group (n = 121) for prevention of renal vein thrombosis.
Post biopsy macroscopic hematuria was 9 percent in aspirin treated group and 7 percent in the control group.
Case–control study of patients receiving a kidney transplant / To study postoperative surgical-site hemorrhage after kidney Transplantation: incidence, risk factors, and outcomes. Authors also analyzed 86/354 patients who were taking antiplatelet.
Bleeding was not significant in KTR with antiplatelet as compared to those who were not on antiplatelet. (0.70, 2.27) P value=0.43]
Retrospective cohort study of kidney transplant recipients who received a transplant from 2008-2014 and had a pre-transplant diagnosis of coronary artery disease and receiving dual antiplatelet.
Transfused during transplant hospitalization 30.3% in those on dual antiplatelet as compared to 15.7% who were not on dual antiplatelet. (P value 0.03)
A retrospective cohort study of consecutive adult living- and deceased-donor kidney-only recipients. Consecutive adult kidney-only recipients from taking aspirin alone (ASA), ASA and Plavix® (DUA), or no Antiplatelet therapy at the time of transplantation were assessed. The primary outcome was at least one blood transfusion during or within 5 days of transplantation. Secondary outcomes included many including reoperation for bleeding.
Blood transfusion was required in 34.6% within 5 days of kidney transplantation. Perioperative blood transfusion was given in 27.8% of patients in the NONE group, 52.2% of cases in the DUAL group, and42.2% of cases in the ASA group (p<0.01) suggesting an association of ASA and DUAL with blood transfusion on univariate analysis. Antiplatelet therapy, either as DUAL or ASA alone, was not associated with reoperation for bleeding (1.0%, 0.0%, 1.5% p = 0.79)
Retrospective chart review of thirteen patients who had received enoxaparin within 10 days of kidney or kidney-pancreas transplantation. Major bleeding events were defined as intracranial or retroperitoneal bleeding, or a decrease in hemoglobin of greater than 2 g/dl.
Nine (69%) of the 13 patients had confirmed major bleeding events and required blood transfusions.
The objective of our study was to report the incidence of bleeding after imaging- guided percutaneous core biopsy at a single center using a standardized technique.
The incidence of bleeding in kidney biopsy, 0.7%; highest than the rest of organs. No statistically significant difference in the major bleeding complication rates was seen between patients who took aspirin within 10 days before biopsy compared with those who did not took aspirin.
Journal of vascular and interventional radiology JVIR / 2017
Retrospective analysis to determine if patient aspirin exposure and timing affect bleeding risk after renal allograft biopsy. Four groups were analyzed which included no aspirin exposure 10 days, exposure within 8-10 days, exposure within 4-7 days and 0-3 days.
Aspirin use was not significantly associated with increased risk of bleeding complication except for use of 325 mg of aspirin within 3 days of biopsy (any complication OR 3.87 , 13.4], P = .032; major complication OR 6.30 , 31.3], P = .024).
Retrospective data review /This study aimed to describe the incidence of major bleeding after biopsy in a single center over a 15-year period and examine factors associated with major bleeding. Aspirin was routinely continued
Aspirin was taken by 327 / 1509 patients. There was no significant increase in the risk of major bleeding (P=0.93).
